833 related articles for article (PubMed ID: 25355681)
1. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Berghoff AS; Kiesel B; Widhalm G; Rajky O; Ricken G; Wöhrer A; Dieckmann K; Filipits M; Brandstetter A; Weller M; Kurscheid S; Hegi ME; Zielinski CC; Marosi C; Hainfellner JA; Preusser M; Wick W
Neuro Oncol; 2015 Aug; 17(8):1064-75. PubMed ID: 25355681
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
6. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
9. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
10. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
12. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
13. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
16. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
20. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]